[go: up one dir, main page]

AU2001259230A1 - Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions - Google Patents

Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions

Info

Publication number
AU2001259230A1
AU2001259230A1 AU2001259230A AU5923001A AU2001259230A1 AU 2001259230 A1 AU2001259230 A1 AU 2001259230A1 AU 2001259230 A AU2001259230 A AU 2001259230A AU 5923001 A AU5923001 A AU 5923001A AU 2001259230 A1 AU2001259230 A1 AU 2001259230A1
Authority
AU
Australia
Prior art keywords
topathogenic
autoantibodies
polyclonal
inhibition
blocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259230A
Inventor
Samuel Strober
Defu Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2001259230A1 publication Critical patent/AU2001259230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001259230A 2000-04-28 2001-04-27 Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions Abandoned AU2001259230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20028500P 2000-04-28 2000-04-28
US60200285 2000-04-28
PCT/US2001/013728 WO2001082960A1 (en) 2000-04-28 2001-04-27 Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions

Publications (1)

Publication Number Publication Date
AU2001259230A1 true AU2001259230A1 (en) 2001-11-12

Family

ID=22741064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259230A Abandoned AU2001259230A1 (en) 2000-04-28 2001-04-27 Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions

Country Status (2)

Country Link
AU (1) AU2001259230A1 (en)
WO (1) WO2001082960A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002315115B2 (en) * 2002-06-14 2008-10-16 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer Methods of treating and preventing colitis involving IL-13 and NK-T cells
ES2378767T3 (en) 2003-12-23 2012-04-17 Crucell Holland B.V. Human binding molecule against CD1a
EP1566439A1 (en) * 2004-02-20 2005-08-24 Nestec S.A. Preventing or treating obesity
EP2534487B1 (en) * 2010-02-12 2015-11-04 Yeda Research and Development Co. Ltd. Diagnosis of systemic lupus erythematosus (sle)
JP2017503169A (en) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド Diagnosis of systemic lupus erythematosus using oligonucleotide antigens
CA2975078A1 (en) 2015-01-27 2016-08-04 Lava Therapeutics B.V. Single domain antibodies targeting cd1d
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods

Also Published As

Publication number Publication date
WO2001082960A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU1687500A (en) Antihuman vegf monoclonal antibody
EP2336187B8 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
AU7863794A (en) Antihuman tyrosinase monoclonal antibody
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
NO20031327D0 (en) Closing device for blocking an opening
AU2001286979A1 (en) Tileable field-programmable gate array architecture
IL156030A0 (en) Humanized antibodies
AU2001234125A1 (en) Antibody library
PL366307A1 (en) Humanized anti-lt-beta-r antibodies
EP1572077A3 (en) Uses of monoclonal antibody 8h9
AU2001261701A1 (en) Cover damping mechanism
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2001250970A1 (en) Microphone with range switching
AU2001259230A1 (en) Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions
AU2003220079A1 (en) Uses of monoclonal antibody 8h9
AU5937598A (en) Humanized anti-human Fas antibody
AU5974000A (en) Lo-cd2b antibody and uses thereof for inhibiting t cell activation and proliferation
AU2002216847A1 (en) Epitopes of pai-1
DE60121575D1 (en) TAP WITH SECONDARY OPENING
DE60119667D1 (en) Charge control agent and toner containing the same
AU2001296915A1 (en) Inhibition of antigen presentation with poorly catabolized polymers
AU2001268040A1 (en) Methods and compounds for inhibiting mrp1
AU2002242447A1 (en) Use of polyclonal immunoglobulins